At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Ascentage Pharma Group International shared results from a Phase Ib study on olverembatinib (HQP1351) combined with blinatumomab, targeting patients with relapsed or refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL) and lymphoid blast phase chronic myeloid leukemia (CML-LBP). The study highlighted a 91% complete response rate among participants, with 67% achieving BCR::ABL1 negativity, showcasing the treatment's effectiveness. The safety profile was manageable, with most adverse events being grade 1-2. Olverembatinib, a third-generation BCR-ABL inhibitor, is already approved in China for specific CML indications and included in the National Reimbursement Drug List. Ascentage is advancing multiple Phase III trials for olverembatinib, which have been cleared by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), indicating strong international interest in this therapy. The results signify a potential breakthrough in treating these challenging hematologic malignancies, addressing significant unmet needs in patient care.